Announcement
Lifevision Healthcare, a pharmaceutical manufacturing company established in 2010 and headquartered in Chandigarh, has issued a press release stating that it is expanding its third‑party manufacturing capabilities to serve clients seeking reliable production of tablets, capsules, syrups, softgels, powders, ointments and other dosage forms.
Service Offering
The company now offers comprehensive contract manufacturing solutions covering a wide array of dosage forms, including tablets, capsules, syrups, softgels, powders, ointments and additional pharmaceutical formulations. These services are positioned to enable pharma companies, distributors and marketers to launch or extend product lines without the need to invest in their own manufacturing facilities.
Manufacturing Facilities and Standards
Lifevision Healthcare operates its production unit in Baddi, Himachal Pradesh, while its corporate office remains in Chandigarh. The manufacturing operations are reported to conform to ISO, WHO and Good Manufacturing Practice (GMP) certifications, supported by modern infrastructure, advanced machinery, quality‑control laboratories, research & development capabilities, and professional staffing.
Product and Therapeutic Portfolio
The firm’s manufacturing portfolio spans multiple therapeutic categories, namely antibiotics, cardiac and diabetic medicines, gynae products, paediatric formulations, proton‑pump inhibitor (PPI) and gastro‑intestinal products, nutraceuticals, dental products and other specialized formulations. This breadth allows clients to access a single manufacturing partner for diverse product lines.
Benefits to Clients
According to the release, partnering with Lifevision Healthcare provides clients with immediate access to established production facilities, technical expertise, stringent quality‑control procedures, packaging solutions and a reliable supply chain, allowing them to focus on brand building, marketing, sales and distribution activities.
Industry Context
The announcement highlights the growing trend toward flexible, third‑party manufacturing in India, which offers pharmaceutical firms the option to leverage experienced manufacturers rather than building new plants, thereby reducing capital expenditure and accelerating time‑to‑market.
Disclaimer
The press release is distributed under an arrangement with NRDPL, and PTI disclaims editorial responsibility for its content.